{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:46:41Z","timestamp":1783648001845,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG27233"],"award-info":[{"award-number":["IG27233"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG23009"],"award-info":[{"award-number":["IG23009"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119090","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:08:03Z","timestamp":1770721683000},"page":"119090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-0025","authenticated-orcid":false,"given":"Mariangela","family":"Tamburello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-0916","authenticated-orcid":false,"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Boldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bonera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Faustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8531-7730","authenticated-orcid":false,"given":"Barbara","family":"Buffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Giugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-4235","authenticated-orcid":false,"given":"Marika","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7243-0673","authenticated-orcid":false,"given":"Mattia","family":"Carini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duilio","family":"Brugnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido Alberto Massimo","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6922-1934","authenticated-orcid":false,"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2026.119090_bib1","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2-03","key":"10.1016\/j.biopha.2026.119090_bib2","first-page":"109","article-title":"Advanced adrenocortical carcinoma - what to do when first-line therapy fails?","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"5","key":"10.1016\/j.biopha.2026.119090_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/030089169207800512","article-title":"Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases","volume":"78","author":"Berruti","year":"1992","journal-title":"Tumori"},{"issue":"10","key":"10.1016\/j.biopha.2026.119090_bib4","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3","article-title":"Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer","volume":"83","author":"Berruti","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2026.119090_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.biopha.2026.119090_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia Experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.biopha.2026.119090_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14656566.2022.2106128","article-title":"Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?","volume":"23","author":"Cremaschi","year":"2022","journal-title":"Expert Opin. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119090_bib9","first-page":"121","article-title":"Progesterone induces cell apoptosis via the CACNA2D3\/Ca2+\/p38 MAPK pathway in endometrial cancer","volume":"43","author":"Kong","year":"2020","journal-title":"Oncol. Rep."},{"issue":"17","key":"10.1016\/j.biopha.2026.119090_bib10","first-page":"3959","article-title":"Effects of estradiol and progesterone on the growth of HeLa cervical cancer cells","volume":"21","author":"Liu","year":"2017","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1556\/2060.2020.00034","article-title":"The apoptotic effects of progesterone on breast cancer (MCF-7) and human osteosarcoma (MG-636) cells","volume":"107","author":"Motamed","year":"2020","journal-title":"Physiol. Int"},{"issue":"23","key":"10.1016\/j.biopha.2026.119090_bib12","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJM200406033502319","article-title":"Estrogen plus progestin and colorectal cancer in postmenopausal women","volume":"350","author":"Sch\u00fcrmann","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119090_bib13","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1210\/jc.2016-2414","article-title":"Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study","volume":"101","author":"Fiorentini","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12020-018-1795-x","article-title":"In vitro antitumor activity of progesterone in human adrenocortical carcinoma","volume":"63","author":"Fragni","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.biopha.2026.119090_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076829","article-title":"Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines","volume":"24","author":"Tamburello","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.0001-6349.2005.00759.x","article-title":"Role of progestins in contraception","volume":"84","author":"Erkkola","year":"2005","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"6 Pt 2","key":"10.1016\/j.biopha.2026.119090_bib17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/0002-9378(92)91401-U","article-title":"The role of progestins in hormone replacement therapy","volume":"166","author":"Lobo","year":"1992","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119090_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cellbi.2006.11.013","article-title":"Medroxyprogesterone and tamoxifen augment anti-proliferative efficacy and reduce mitochondria-toxicity of epirubicin in FM3A tumor cells in vitro","volume":"31","author":"Altinoz","year":"2007","journal-title":"Cell Biol. Int"},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<483::AID-CNCR9>3.0.CO;2-L","article-title":"A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185)","volume":"77","author":"Cobau","year":"1996","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2026.119090_bib20","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/jcm12103388","article-title":"Understanding progestins: from basics to clinical applicability","volume":"12","author":"Garc\u00eda-S\u00e1enz","year":"2023","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119090_bib21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.1988.6.7.1098","article-title":"Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association","volume":"6","author":"Muss","year":"1988","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib22","first-page":"Cd004310","article-title":"Megestrol acetate for treatment of anorexia-cachexia syndrome","volume":"2013","author":"Ruiz Garcia","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"18","key":"10.1016\/j.biopha.2026.119090_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184491","article-title":"Feasibility and activity of megestrol acetate in addition to etoposide, doxorubicin, cisplatin, and mitotane as first-line therapy in patients with metastatic\/unresectable adrenocortical carcinoma with low performance Status","volume":"15","author":"Turla","year":"2023","journal-title":"Cancers"},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119090_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","article-title":"Adrenocortical cell lines","volume":"228","author":"Rainey","year":"2004","journal-title":"Mol. Cell Endocrinol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119090_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091439","article-title":"A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma","volume":"11","author":"Sigala","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119090_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-022-03112-w","article-title":"An update on adrenocortical cell lines of human origin","author":"Sigala","year":"2022","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.biopha.2026.119090_bib27","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119090_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119090_bib29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/endrev\/bnac012","article-title":"Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies","volume":"43","author":"Lerario","year":"2022","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119090_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119090_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119090_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.biopha.2026.119090_bib33","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/bit.25950","article-title":"A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening","volume":"113","author":"Skardal","year":"2016","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biopha.2026.119090_bib34","series-title":"bookTitle= Primary Adrenal Malignancies","first-page":"1","article-title":"a, Epidemiology, Presentation, Staging, and Prognostic Factors in Adrenocortical Carcinoma","year":"2025"},{"issue":"1","key":"10.1016\/j.biopha.2026.119090_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae159","article-title":"Development and characterization of 3-dimensional cell culture models of adrenocortical carcinoma","volume":"166","author":"Feely","year":"2024","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.biopha.2026.119090_bib36","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tem.2017.05.006","article-title":"Progesterone-mediated non-classical signaling","volume":"28","author":"Garg","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2026.119090_bib37","doi-asserted-by":"crossref","first-page":"15508","DOI":"10.1038\/s41598-023-42659-0","article-title":"A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity","volume":"13","author":"Dedhia","year":"2023","journal-title":"Sci. Rep."},{"issue":"29","key":"10.1016\/j.biopha.2026.119090_bib38","doi-asserted-by":"crossref","first-page":"45745","DOI":"10.18632\/oncotarget.9935","article-title":"The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance","volume":"7","author":"Breslin","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2026.119090_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020227","article-title":"A 3D view of colorectal cancer models in predicting therapeutic responses and resistance","volume":"13","author":"Reidy","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119090_bib40","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.18632\/oncotarget.13857","article-title":"Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment","volume":"8","author":"D\u00e4ster","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2026.119090_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119090_bib42","first-page":"3504","article-title":"Regulation of growth saturation and development of necrosis in EMT6\/Ro multicellular spheroids by the glucose and oxygen supply","volume":"46","author":"Freyer","year":"1986","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119090_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/bjc.1986.58","article-title":"Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids","volume":"53","author":"Mueller-Klieser","year":"1986","journal-title":"Br. J. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:42:50Z","timestamp":1781880170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S0753332226001228"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119090","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119090"}}